Dapagliflozin was known as a treatment of choice for glucose control in diabetes patients. Recently, attention has focused on its renoprotective effect through mechanism of hemodynamic and non-hemodynamic. We aimed to assess the effect of dapagliflozin on two key markers of kidney disease: urine albumin:creatinine ratio (UACR) and estimated-glomerular filtration rate (eGFR). A literature search was performed in PubMed database within the past ten years to identify randomized controlled trials (RCTs) which assessed the effect of dapagliflozin on renal markers including UACR (mg/g) and eGFR (mL/min/1.73 m2) in type 2 diabetes patients. The results were reported as mean differences (MD) and confidence interval (CI) using a random-effects model. A total of 88 participants from two RCTs were included. We found that dapagliflozin significantly decreased UACR compared to placebo [-39.78; 95% CI: -56.56 to -23.01; p < 0.00001]. No difference was found on eGFR between the two group [-1.89; 95% CI: -7.08 to 3.29; p = 0.47]. Dapagliflozin might be beneficial in improving albuminuria and slowing down the progression of kidney disease. Further studies with larger population and longer period of treatment are needed to assess its effect and safety for long-term use.